One-a-day pill for HIV offers a new option for patients with treatment resistance

A Lancet study tested a new single-tablet combining bictegravir and lenacapavir in about 550 people on complex HIV regimens and reported results comparable to their prior multi‑drug treatments; the article mentions Gilead Sciences plans an FDA filing and a possible launch in the second half of the year.

Researchers published a study testing a new single-tablet HIV pill that combines bictegravir and lenacapavir. The trial involved about 550 people who were on complex, multi‑pill regimens because of resistance or other treatment challenges. The article mentions the research was supported by Gilead Sciences and was conducted at more than 90 sites internationally. Gilead said it will seek U.S. regulatory approval and has indicated a potential launch in the second half of the year. Key facts: - The study, published online Feb. 25 in The Lancet, tested a single daily tablet combining bictegravir and lenacapavir in roughly 550 people on complex HIV regimens. - Researchers reported the single-tablet performed as well as participants' existing multi-drug regimens and was reported to be comparable to an established single-tablet option in a separate presentation. - The article mentions Gilead Sciences plans to file with the U.S. Food and Drug Administration in the near future and cites ongoing questions about pricing and availability, especially in lower-income countries. Summary: The reported results indicate a simplified single-tablet option could replace complex regimens for some people with HIV who have developed resistance or face treatment interactions. The next procedural step noted in the article is a planned FDA filing by the manufacturer; broader access and pricing decisions remain undetermined at this time.